Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled “If NIH Challenges Genzyme’s Patents, Does Anyone Care?” Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.
Related News
13 March 2025
In the News
Foley Attorneys Featured for Automotive Roundtable
Foley & Lardner LLP features in the Forbes article, "Threat Of Tariffs And Ending Tax Credits Could Tank EV Sales, Hurt Suppliers," for a roundtable discussion hosted in the firm's Detroit office on the state of the automotive industry.
12 March 2025
In the News
Chanley Howell Highlights Balance Necessary for AI Agents
Foley & Lardner LLP partner Chanley Howell described balance as key to the success of artificial intelligence agents in the IT Brew article, "How an AI pro puts ‘handbrakes’ on agentic decisions."
10 March 2025
In the News
Judith Waltz Quoted on HHS Bypass of Public Comment Period
Foley & Lardner LLP partner Judith Waltz commented in the Report on Medicare Compliance article, "HHS May Go Straight to Final Rules, Bypassing Public Comments," published by the Health Care Compliance Association.